ICMR Focuses On Two-Dose Vax, Fits Current Covishield Gap | India News
Dr Samiran Panda, head of the epidemiology department at ICMR, told TOI that from now on, the supreme biomedical research body will stress the importance of achieving greater coverage with two-way vaccination. doses. “As cases of Omicron are mild not only in India but worldwide, there should be no knee-jerk reaction such as the introduction of a third dose or the recommendation of any change in the interval of doses of Covishield. “, did he declare.
“A decision as to whether a third dose would be needed for immunocompromised people would be made later,” Dr Panda said.
He said the scientific evidence for a booster dose for Indian terrain was being assessed and the technical advisory group would make an announcement about it. Dr Panda said public health should focus on double vaccination and completing the adult vaccination program now, as the two-dose vaccination strategy seemed to work well in the Indian context.
At the request of states like Maharashtra, Kerala and Karnataka to close the gap between the two doses of Covishield, the ICMR scientist said scientific evidence for the national reality showed the interval to be good .
Virologist Dr Shahid Jameel said a booster would increase the number of circulating antibodies and was found to increase protection against symptomatic infections with Omicron. “We don’t know how well two doses continue to protect against serious illness. In the UK, those who have received the AstraZeneca vaccine are being boosted with the Pfizer or Moderna mRNA vaccine. A third dose of AstraZeneca will not be given. very effective because of its nature, ”he said.